Table 3.
Univariate and multivariate logistic progression analysis of baseline variables for remission within 6 months in primary PMNs.
| Univariate Analysis | Multivariate Analysis | |||
|---|---|---|---|---|
| OR: 95% CI | p Value | OR: 95% CI | p Value | |
| Male (%) | 1.20 (0.76–1.87) | 0.43 | ||
| Age (y) | 0.997 (0.98–1.01) | 0.73 | ||
| Microscopic Hematuria (%) | 0.95 (0.61–1.46) | 0.81 | ||
| Urine protein (g/24 h) | 0.94 (0.89–0.99) | 0.046 | 0.92 (0.85–0.98) | 0.02 |
| Albumin (g/L) | 1.03 (0.99–1.06) | 0.11 | ||
| eGFR-EPI (mL/min × 1.73m2) | 0.999 (0.99–1.01) | 0.92 | ||
| Uric acid (umol/L) | 0.999 (0.997–1.002) | 0.90 | ||
| Hypertension (%) | 0.84 (0.55–1.31) | 0.44 | ||
| Diabetes Mellitus (%) | 0.41 (0.22–0.79) | 0.01 | 0.47 (0.24–0.94) | 0.03 |
| Immunosuppressive therapy (%) | 1.81 (1.01–2.98) | 0.02 | 3.19 (1.78–5.73) | <0.01 |
| Pathology stage (%) | ||||
| I | reference | |||
| II | 0.78 (0.45–1.35) | 0.38 | ||
| III + IV | 0.87 (0.41–1.84) | 0.71 | ||
| Tubulo-interstitial lesions ≥ 25 (%) | 0.59 (0.13–2.69) | 0.50 | ||
| Serum PLA2R ab and glomerular PLA2R staining | ||||
| SAb−/GAg− | reference | reference | ||
| SAb+/GAg− | 0.07 (0.01–0.70) | 0.02 | 0.06 (0.01–0.56) | 0.01 |
| SAb+/GAg+ | 0.34 (0.16–0.71) | <0.01 | 0.30 (0.14–0.66) | <0.01 |
| SAb−/GAg+ | 0.68 (0.31–1.52) | 0.35 | 0.70 (0.30–1.61) | 0.40 |